The Effect of Semaglutide on Cardiovascular Markers and Liver Function
Conditions: Diabetes Type 2 Interventions: Drug: Semaglutide, 1.0 mg/mL; Drug: Dipeptidyl Peptidase 4 inhibitor Sponsors: Attikon Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Hospitals | Liver | Research | Urology & Nephrology